BMJ2d
EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis
15 Department of Radiology. Leiden University Medical Centre, Leiden, The Netherlands 16 Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ2d
OP0182 SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TitAIN TRIAL
Background Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs and symptoms ...
BMJ2d
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era
Correspondence to Ping-Hsuan Hsieh, Health Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow G12 8RZ, UK; p.hsieh.1{at}research.gla.ac.uk ...
BMJ6d
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Correspondence to Dr Elizabeth R Volkmann, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; evolkmann{at}mednet.ucla.edu ...
BMJ1d
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000
Objective: To assess the reliability of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000 index in routine practice and its ability to capture disease activity as compared with the ...
BMJ2d
AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers
Background Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining a favorable safety profile and clinical efficacy in patients after 4 weeks of dosing with rheumatoid arthritis (RA ...
BMJ2d
OP0195 VASCULARIZED THREE-DIMENSIONAL MODELS OF HUMAN SKIN FIBROSIS
1 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany Objectives: Here we ...
BMJ3d
OP0273 THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI) IN A SYSTEMIC SCLEROSIS COHORT WITH 10-YEARS FOLLOW-UP
Background: Systemic Sclerosis (SSc) is characterized by increased mortality and organ damage accrual. A composite SSc Damage Index was recently developed by the Scleroderma Clinical Trials Consortium ...
BMJ11d
Single-cell transcriptome analyses reveal disturbed decidual homoeostasis in obstetric antiphospholipid syndrome
Correspondence to Dr Lang Qin, Reproductive Medical Center, Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, ...
BMJ3d
Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis
Dr R M Aspden, Department of Orthopaedics, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB9 2ZD. OBJECTIVE To determine the material properties of the subchondral bone plate in ...
BMJ3d
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA. However, the question of which animal model is most predictive of therapeutic efficacy in human ...
BMJ3d
Psoriasis: epidemiology, clinical features, and quality of life
Psoriasis is a common chronic, recurrent, immune mediated disease of the skin and joints. It can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affected ...